Current Report Filing (8-k)
27 April 2020 - 10:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
April 27, 2020
Date of report (Date of earliest event reported)
Axsome Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37635
|
|
45-4241907
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
200 Broadway, 3rd Floor
New York, New York
(Address of principal executive offices)
|
|
10038
(Zip Code)
|
Registrant’s telephone number, including
area code (212) 332-3241
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section
12(b) of the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
Common Stock, Par Value $0.0001 Per Share
|
|
AXSM
|
|
The Nasdaq Global Market
|
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
On April 27, 2020, Axsome Therapeutics,
Inc. (the “Company”) issued a press release announcing that AXS-05 met the prespecified primary endpoint and significantly
improved agitation in patients with Alzheimer’s disease in the Company’s ADVANCE-1 Phase 2/3 trial. The Company will
host a conference call at 8:00 a.m. ET on April 27, 2020 to discuss the topline results of the ADVANCE-1 trial.
The full text of the press release is filed
as Exhibit 99.1 hereto and is incorporated herein by reference. A copy of the presentation that the Company will use in connection
with the conference call is filed as Exhibit 99.2 hereto and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
Axsome Therapeutics, Inc.
|
|
|
Dated: April 27, 2020
|
By:
|
/s/ Herriot Tabuteau, M.D.
|
|
Name:
|
Herriot Tabuteau, M.D.
|
|
Title:
|
President and Chief Executive Officer
|
|
|
|
|
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2024 to May 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From May 2023 to May 2024